Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus

Li, Shasha; Liu, Wenli; Chen, Yangzhen; Wang, Liqin; An, Wenlin; An, Xiaoping; Song, Lihua; Tong, Yigang; Fan, Huahao; Lu, Chenyang

doi:10.1093/bib/bbaa387

Cited by 49 publications

(35 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to molnupiravir and paxlovid, three more oral anti-COVID-19 drugs are in phase 3 clinical trials: the 3CL protease inhibitors s217622 (developed by Shionogi, Japan), the RdRp inhibitor AT-527 (jointly developed by Roche, Switzerland and Atea, USA), and the SARS-CoV-2 ACE2 and TMPRSS2 antagonist proxalutamide (initiated by Kintor Pharma, China) ( 14 ). Moreover, our group found that cepharanthine can effectively inhibit the entry and replication of GX_P2V, which has high homology with SARS-CoV-2, showing the potential antiviral activity of cepharanthine against SARS-CoV-2 ( 97 , 98 ). Zhang et al.…”

Section: Conclusion and Perspectivementioning

confidence: 98%

Molnupiravir and Its Antiviral Activity Against COVID-19

Tian

Pang

et al. 2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat and economic burden. The pandemic is still ongoing and the SARS-CoV-2 variants are still emerging constantly, resulting in an urgent demand for new drugs to treat this disease. Molnupiravir, a biological prodrug of NHC (β-D-N(4)-hydroxycytidine), is a novel nucleoside analogue with a broad-spectrum antiviral activity against SARS-CoV, SARS-CoV-2, Middle East respiratory syndrome coronavirus (MERS-CoV), influenza virus, respiratory syncytial virus (RSV), bovine viral diarrhea virus (BVDV), hepatitis C virus (HCV) and Ebola virus (EBOV). Molnupiravir showed potent therapeutic and prophylactic activity against multiple coronaviruses including SARS-CoV-2, SARS-CoV, and MERS-CoV in animal models. In clinical trials, molnupiravir showed beneficial effects for mild to moderate COVID-19 patients with a favorable safety profile. The oral bioavailability and potent antiviral activity of molnupiravir highlight its potential utility as a therapeutic candidate against COVID-19. This review presents the research progress of molnupiravir starting with its discovery and synthesis, broad-spectrum antiviral effects, and antiviral mechanism. In addition, the preclinical studies, antiviral resistance, clinical trials, safety, and drug tolerability of molnupiravir are also summarized and discussed, aiming to expand our knowledge on molnupiravir and better deal with the COVID-19 epidemic.

show abstract

Section: Conclusion and Perspectivementioning

confidence: 98%

Molnupiravir and Its Antiviral Activity Against COVID-19

Tian

Pang

et al. 2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Among the 231 articles (PubMed and Google Scholar), 91 were retained [ 3 , 12 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 ,…”

Section: Update (16 June 2021) On Studies With Fiasmas In the Sars-cov-2 Infectionmentioning

confidence: 99%

Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection

Loas

Corre

2021

Pharmaceuticals

View full text Add to dashboard Cite

The SARS-CoV-2 outbreak is characterized by the need of the search for curative drugs for treatment. In this paper, we present an update of knowledge about the interest of the functional inhibitors of acid sphingomyelinase (FIASMAs) in SARS-CoV-2 infection. Forty-nine FIASMAs have been suggested in the treatment of SARS-CoV-2 infection using in silico, in vitro or in vivo studies. Further studies using large-sized, randomized and double-blinded controlled clinical trials are needed to evaluate FIASMAs in SARS-CoV-2 infection as off-label therapy.

show abstract

“…This alkaloid inhibits SARS-CoV-2 entry in vitro at an IC 50 of 0.35 μM without any evident toxicity profile (selectivity index, [SI] > 70) [ 136 ]. Furthermore, the cell death cascade induced by the cellular stress response is another key target for SARS-CoV-2 [ 137 ]. It is worth noting that this bisbenzylisoquinoline alkaloid, with a good safety profile, is an approved drug in Japan since the 1950s and is used to treat acute and chronic diseases [ 132 ], highlighting that cepharanthine can serve as a potential therapeutic candidate for the treatment of SARS-CoV-2 infection.…”

Section: Natural Products In Combination With the Fda-approved Drugs Inhibit Sars-cov-2mentioning

confidence: 99%

Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer

Yang

Wang

2021

Biomedicines

View full text Add to dashboard Cite

As a public health emergency of international concern, the highly contagious coronavirus disease 2019 (COVID-19) pandemic has been identified as a severe threat to the lives of billions of individuals. Lung cancer, a malignant tumor with the highest mortality rate, has brought significant challenges to both human health and economic development. Natural products may play a pivotal role in treating lung diseases. We reviewed published studies relating to natural products, used alone or in combination with US Food and Drug Administration-approved drugs, active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and lung cancer from 1 January 2020 to 31 May 2021. A wide range of natural products can be considered promising anti-COVID-19 or anti-lung cancer agents have gained widespread attention, including natural products as monotherapy for the treatment of SARS-CoV-2 (ginkgolic acid, shiraiachrome A, resveratrol, and baicalein) or lung cancer (daurisoline, graveospene A, deguelin, and erianin) or in combination with FDA-approved anti-SARS-CoV-2 agents (cepharanthine plus nelfinavir, linoleic acid plus remdesivir) and anti-lung cancer agents (curcumin and cisplatin, celastrol and gefitinib). Natural products have demonstrated potential value and with the assistance of nanotechnology, combination drug therapies, and the codrug strategy, this “natural remedy” could serve as a starting point for further drug development in treating these lung diseases.

show abstract

Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus

Cited by 49 publications

References 49 publications

Molnupiravir and Its Antiviral Activity Against COVID-19

Molnupiravir and Its Antiviral Activity Against COVID-19

Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection

Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer

Contact Info

Product

Resources

About